Expired activity
Please go to the PowerPak homepage and select a course.

Obesity Forum®: Getting Engaged in Obesity Care

This continuing pharmacy education activity is provided by Vindico Medical Education

This activity is supported by educational grants from Lilly and Novo Nordisk, Inc.

Activity Description

Obesity is an increasingly prevalent chronic condition associated with substantial risks of morbidity and mortality. It is also a risk factor for some of the leading causes of preventable death, including cardiovascular disease, stroke, type 2 diabetes mellitus, sleep apnea, gallbladder disease, osteoarthritis, and certain types of cancer. With prevalence continuing to escalate, it is predicted that 1 in 2 Americans will have obesity by 2030. Among the groups most at risk for severe obesity are women, Black non-Hispanic adults, low-income adults, and youths aged 2 to 19 years—of whom 19.3% are estimated to have obesity. Currently, underdiagnosis and undertreatment of obesity are frequent due to shortcomings in patient evaluation, uncertainty regarding approaches that support adherence to behavioral and lifestyle modifications, and a lack of thorough knowledge concerning the efficacy and safety of pharmacologic and surgical interventions. Patients with overweight or obesity often have multiple health concerns and may see several providers; therefore, a multidisciplinary management approach is required. This activity aims to provide health care professionals with guidance on the appropriate use of therapies as well as strategies for delivering individualized care to patients of any age with overweight or obesity via interprofessional strategies.

Course Chair

Robert F. Kushner, MD, MS, FACP, FTOS, DABOM
Professor, Departments of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Director, Center for Lifestyle Medicine
Northwestern Medicine
Chicago, IL


Ania M. Jastreboff, MD, PhD, DABOM
Associate Professor of Medicine, Endocrinology & Metabolism
Associate Professor of Pediatrics, Pediatric Endocrinology
Director, Weight Management and Obesity Prevention, Yale Stress Center
Co-Director, Yale Center for Weight Management
Yale University School of Medicine
New Haven, CT

Scott Kahan, MD, MPH, FTOS, DABOM
Director, National Center for Weight and Wellness
Johns Hopkins Bloomberg School of Public Health
Washington, DC

Donna H. Ryan, MD, FACP, FTOS
Professor Emerita
Pennington Biomedical Research Center
Louisiana State University
Baton Rouge, LA

Christopher D. Still, DO, FACP, FTOS, DABOM
Professor of Medicine
Department of Clinical Sciences
Geisinger Commonwealth School of Medicine
Medical Director, Center for Nutrition & Weight Management
Director, Geisinger Obesity Institute
Geisinger Health System
Danville, PA

Planning Committee Members

Holly Herrington, MS, RD, LDN, CDCES
Advanced Clinical Dietitian
Center for Lifestyle Medicine and Bariatric Surgery
Northwestern Memorial Hospital
Chicago, IL

Patricia Nece, JD
Patient Advocate
Chair of the Board of Directors
Obesity Action Coalition
Alexandria, VA


acpeVindico Medical Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Fee Information: There is no fee for this activity.
Estimated time to complete activity:
135 minutes


December 23, 2022


December 22, 2023

Designation Statement

This program is acceptable for 2.25 contact hours of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-22-041-H01-P, effective December 23, 2022. This is a knowledge-based activity and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.

This enduring material is approved for 1 year from the date of original release, December 23, 2022, to December 22, 2023.


The intended audience for this activity is family medicine physicians, internists, endocrinologists, pharmacists, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients with overweight and obesity.


To participate in this CE activity, you must read the learning objectives, answer the pretest questions, view the content, and complete the CE posttest and evaluation within a maximum of 60 days of participating in the activity. To answer the questions, click on your selected choice for each answer then proceed to the next question. Once completed, click on the Grade Exam button at the bottom of the page. Your posttest will automatically be graded. If you successfully complete the posttest (score of 66% or higher, correctly answering 8 out of the 12 posttest questions), your statement of participation will be made available immediately. Click on the View Statement of Participation link and print the statement for your records. If you receive a score lower than 66%, you will receive a message notifying you that you did not pass the posttest. You will have 2 opportunities to pass the posttest. To receive Credit, you must provide your date of birth and NABP number. All Credit information will be uploaded into CPE monitor within 30 days.


Vindico Medical Education adheres to the Accreditation Council for Pharmacy Education (ACPE's) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Course Chair, Faculty, and Planning Committee Members report the following relevant financial relationship(s)

Holly Herrington, MS, RD, LDN, CDCES
No relevant financial relationships to disclose.

Ania M. Jastreboff, MD, PhD, DABOM
Advisor: Boehringer Ingelheim, Intellihealth, Lilly, Novo Nordisk, Pfizer, Rhythm Pharmaceuticals, Weight Watchers
Individual Stocks and Stock Options: Intellihealth
Multi-center Trials: Lilly, Novo Nordisk, Rhythm Pharmaceuticals

Scott Kahan, MD, MPH, FTOS, DABOM
Consultant: Gelesis, Lilly, Novo Nordisk, Pfizer, Vivus

Robert F. Kushner, MD, MS, FACP, FTOS, DABOM
Consultant: Altimmune, Lilly, Novo Nordisk, Weight Watchers
Independent Research Contractor: Epitomee

Patricia Nece, JD
Relevant Financial Disclosures
Consultant: Novo Nordisk

Donna H. Ryan, MD, FACP, FTOS
Advisor: Altimmune, Calibrate, Gila Therapeutics, Lilly, Novo Nordisk, Real Appeal, Wondr Health, YSOPIA, Zealand
Consultant: Amgen, Epitomee, IFA Celtic, Scientific Intake, Roman, Zealand
Speaker Contracted by Ineligible Company: Novo Nordisk
Independent Research Contractor: Calibrate, Epitomee, Roman, Scientific Intake
SELECT Steering Committee: Novo Nordisk

Christopher D. Still, DO, FACP, FTOS, DABOM
Consultant: Novo Nordisk
Speaker Contracted by Ineligible Company: Novo Nordisk
Independent Research Contractor: Ethicon Endo-Surgery, Novo Nordisk

Planners/Reviewers report the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Upon completion of this program, participants should be better able to:

  • Incorporate knowledge of obesity as a chronic disease characterized by multifactorial etiology, appetite dysregulation, comorbidities/obesity-related complications, and hormonal and metabolic adaptations.
  • Utilize interprofessional strategies to treat overweight and obesity, including shared decision-making and consideration of patient preferences/perspectives.
  • Select "high-risk" patients with obesity and related complications/comorbidities who may benefit from further evaluation and treatment for weight loss.
  • Employ recent clinical evidence regarding the pharmacological management of overweight and obesity in children and adolescents.
  • Apply the pharmacological management of obesity based on evidence-based interventions, patient needs, and recent clinical evidence.
  • Implement bariatric surgery in patients with obesity, including management of post-surgical weight gain.
  • Summarize the long-term pharmacological management of obesity, including clinical evidence for weight regain after cessation of medication.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CPE Questions?

Contact us at cme@vindicoCME.com